Navigation Links
Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
Date:2/26/2008

MONTVALE, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by GlaxoSmithKline in connection with its Avodart(R) (dutasteride) soft gelatin capsules, 0.5mg. The Company believes that it is the first to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for Avodart.

Barr filed its ANDA containing a paragraph IV certification for a generic Avodart product with the U.S. Food & Drug Administration (FDA) in October 2007, and received notification of the application's acceptance for filing in January 2008. Following receipt of the notice from the FDA that Barr's ANDA had been accepted for filing, Barr notified the New Drug Application (NDA) and patent holder.

On February 25, 2008, GlaxoSmithKline filed suit in the U.S. District Court for the District of Delaware to prevent Barr from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

Avodart (dutasteride) had annual sales of approximately $362 million in the U.S., based on IMS sales data for the twelve-month period ending December 2007.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidi
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Icahn Confirms Intention to Nominate Three Directors at Biogen
2. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
3. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
4. Barr Confirms Patent Challenge of Focalin(R) XR
5. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
6. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
7. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
8. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
9. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
10. United States Patent Office Grants CryoCors Request for Patent Interference
11. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 21, 2014 With a larger, ... the new Cole-Parmer® Digital Gear Pump Drive ... to operate for automated process applications. , Simply ... The batch count function counts down and displays ... tracks amount dispensed across multiple cycles. View the ...
(Date:7/21/2014)... , July 21, 2014 ... & USA Cancer Biomaker ... Forecasts ResearchMoz presents this most up-to-date ...   to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, ... Pipeline Analysis. GLOBAL & ...
(Date:7/18/2014)... TARRYTOWN, N.Y. , July 18, 2014 ... report its second quarter 2014 financial and operating results ... markets open.  The Company will host a conference call ... day. Conference Call InformationTo access this ...  A link to the webcast may be accessed from ...
(Date:7/18/2014)... July 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) today ... Directors appointed Co-Chairmen Charles S. Ramat and ... an interim basis, effective immediately. Messrs. Ramat and Freiman ... longer Chief Executive Officer of Neurotrope Bioscience, Inc., (a ... whose employment agreement with Neurotrope Bioscience Inc. terminated as ...
Breaking Biology Technology:New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 3Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 4Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 5Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 6Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 2Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 3Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 4
... , , , Multiporator , , , , , ... Transfection Protocol , Protocol No. 4308 915.026 11/2001 , ... , , , ... line), , , ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , Protocol No. 4308 915.525 01/2002 , ... , , , ... , Cell type , Bacteria, gram positive, ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.540 07/2002 , , ... , , Microorganism , ... Cell type , Bacteria, gram positive, , ...
Cached Biology Technology:Sp20-Ag14 2Sp20-Ag14 3Nocardia asteroides 2Pediococcus spp. 2
(Date:7/21/2014)... Irvine, Calif., July 21, 2014 Dysfunction in ... about 2,000 genes in the brain,s prefrontal cortex ... complex neuropsychiatric disorders, such as schizophrenia, according to ... gene activity in brain cells that receive this ... deficiencies can affect a variety of behavioral and ...
(Date:7/21/2014)... satellites detected 154 hotspots in areas across Riau province ... had increased again following a decline in rainfall. ... far higher than what had been reported one day ... hotspots were scattered in six regencies and municipalities, most ... and the related haze it creates could potentially spread ...
(Date:7/21/2014)... change, due to greenhouse gasses emitted by livestock. New ... and that beef cattle are responsible for far more ... is published by Climactic Change . , ... to climate change. It is released by vehicles, industry, ... greenhouse gas totals. But methane and nitrous oxide are ...
Breaking Biology News(10 mins):UCI researchers find epigenetic tie to neuropsychiatric disorders 2Climate: Meat turns up the heat 2
... with a large-scale "geoengineering" fix, such as having a ... or building tens of millions of chemical filter systems ... But Richard Turco, a professor in ... a member and founding director of UCLA,s Institute of ...
... Rochester have designed a gene that produces a ... in healthy cells., The findings may help address ... ability to specifically and effectively target cancer cells. ... to insert "self-destruct" codes into the modified gene, ...
... Commonwealth University Life Sciences survey shows that eight in 10 ... who want it, and 54 percent say that the benefits ... about genetic research are varied with a plurality of 38 ... known about how to conduct such research safely. About three ...
Cached Biology News:No quick or easy technological fix for climate change, researchers say 2No quick or easy technological fix for climate change, researchers say 3No quick or easy technological fix for climate change, researchers say 4Modified gene targets cancer cells a thousand times more often than healthy cells 2Modified gene targets cancer cells a thousand times more often than healthy cells 3VCU survey: US public supports genetic research, testing and government spending on research 2VCU survey: US public supports genetic research, testing and government spending on research 3
... fast and reliable automation for today's ... development laboratories. Staccato Mini-Workstations offer the ... basic liquid handling and material management ... either Caliper's time proven CLARA™ assay ...
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
... If particles in the submicron range ... development process, measurement and control of particle ... an analyzer that can reliably detect the ... The N5 Submicron Particle Size Analyzer uses ...
...
Biology Products: